Skip to main content
    C

    CorMedix Inc (CRMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.82
    +0.16 (+3.43%)

    Market Cap: $370.64M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    CorMedix Inc (CRMD) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect CorMedix (CRMD) to earn $0.54 per share in the fiscal year ending Dec 31, 2026, on revenue of $336.65M. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 1.50, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy350.0%
    Buy350.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    6

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus falls 81.5% and revenue estimates fall 6.1%.

    Fiscal year ending Dec 31, 2026
    $0.54
    EPS consensus, revenue $336.65M
    Fiscal year ending Dec 31, 2027
    $0.10
    EPS consensus, revenue $316.03M
    Next report
    Mar 3, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.54$0.51 to $0.594$336.65M$334.06M to $344.00M6
    Dec 31, 2027$0.10-$0.10 to $0.234$316.03M$282.40M to $374.57M6

    Quarterly Estimates

    The EPS consensus rises from -$0.17 for the quarter ending Dec 31, 2026 to -$0.01 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.17-$0.25 to -$0.137$54.47M$50.96M to $57.49M7
    Mar 31, 2027-$0.01-$0.01 to -$0.011$66.91M$66.91M to $66.91M1

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 3 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202623
    Fiscal year ending Dec 31, 202700
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 10.2% from $0.49.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.54$0.49$0.50$0.49$0.49+11.2%
    Fiscal year ending Dec 31, 2027$0.10$0.01$0.06$0.06$0.06+58.3%
    Quarter ending Mar 31, 2027-$0.01-$0.02-$0.02N/AN/AN/A

    Frequently Asked Questions About CRMD

    What is the CRMD stock forecast?

    Consensus analyst estimates put CorMedix's EPS at $0.54 for the fiscal year ending Dec 31, 2026, on revenue of $336.65M. The consensus rating from 6 analysts is Buy.

    How do analysts rate CRMD stock?

    Of 6 analysts covering CorMedix, 3 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from CRMD next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.54, with estimates from $0.51 to $0.59 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.10, with estimates from -$0.10 to $0.23 from 4 analysts.

    What revenue do analysts expect from CorMedix next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $336.65M, with estimates from $334.06M to $344.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $316.03M, with estimates from $282.40M to $374.57M.

    How many analysts cover CRMD?

    6 analysts rate CorMedix stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.